Vanguard Global Advisers
PACB icon

Vanguard Global Advisers’s Pacific Biosciences PACB Stock Holding History

Vanguard Global Advisers’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Hold
121,781
– – ﹤0.01% 2491
2026
Q1 		$161K Buy
+121,781
New +$218K ﹤0.01% 2541

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Global Advisers's PACB Position: Q2 2026 in Review

Vanguard Global Advisers held its Pacific Biosciences (PACB) position steady in Q2 2026 at 121,781 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #2491.

Vanguard Global Advisers first reported a position in PACB in Q1 2026 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Vanguard Global Advisers held 121,781 shares of Pacific Biosciences worth $205K as of Q2 2026.
  • Vanguard Global Advisers left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2491 holding.
  • Vanguard Global Advisers first reported a position in Pacific Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.